RespireRx Pharmaceuticals Inc (fka RSPI)

[gfp927z]

Neuro, One aspect of the late June results (RD-2) is that since that trial isn't testing for maintenance of analgesia (only RD-1 tests for that key parameter), we won't have the total picture of where we stand until after getting the RD-1 results later in July.

In addition, we won't be getting any data at all on analgesic maintenance at the highest 2100 mg dose, which could conceivably be the only dose with good efficacy in RD. So that's a potentially serious trial design flaw.

Hopefully it won't matter if 1500 mg has sufficient efficacy in RD-1. But in effect, we're going to have to go through 2 binary events here (RD-2 for RD efficacy, and RD-1 for maintenance of analgesia efficacy), and even after sweating out those there's still a potentially fatal data 'hole' (lack of any maintenance of analgesia data at 2100 mg).